[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"condition:peripheral-primitive-neuroectodermal-tumor":3},{"name":4,"total":5,"recruiting":6,"trials":7,"biomarkers":37,"states":38},"Peripheral Primitive Neuroectodermal Tumor",4,3,[8,16,23,30],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT07321912","Eflornithine (DFMO) for Ewing Sarcoma and Osteosarcoma",[12],"Phase 2","RECRUITING","2026-08-26T02:17:22.949982Z","2026-05-29T15:36:40.187051Z",{"nct_id":17,"title":18,"phases":19,"status":13,"updated_at":21,"content_modified":22},"NCT06441331","Phase I Trial to Determine the Dose and Evaluate the PK and Safety of Lutetium Lu 177 Edotreotide Therapy in Pediatric Participants With SSTR-positive Tumors",[20],"Phase 1","2026-08-26T02:18:55.570428Z","2026-05-05T02:43:26.707134Z",{"nct_id":24,"title":25,"phases":26,"status":13,"updated_at":28,"content_modified":29},"NCT04901702","Study of Onivyde With Talazoparib or Temozolomide in Children With Recurrent Solid Tumors and Ewing Sarcoma",[27],"Phase 1\u002FPhase 2","2026-08-26T02:18:32.765187Z","2026-05-05T02:35:31.688370Z",{"nct_id":31,"title":32,"phases":33,"status":34,"updated_at":35,"content_modified":36},"NCT06068075","Liquid Biopsy in Ewing Sarcoma and Osteosarcoma as a Prognostic And Response Diagnostic: LEOPARD",[],"ACTIVE_NOT_RECRUITING","2026-08-03T02:36:50.517616Z","2026-05-05T02:43:27.834324Z",[],[39,42,45],{"state":40,"count":6,"slug":41},"California","california",{"state":43,"count":6,"slug":44},"Pennsylvania","pennsylvania",{"state":46,"count":6,"slug":47},"Texas","texas"]